Synlogic announces International Nonproprietary Name selection for SYNB1934

Synlogic announced that the International Nonproprietary Names, INN, Expert Committee of the World Health Organization, WHO-INN, has selected “labafenogene marselecobac” for the nonproprietary name of the company’s investigational drug for phenylketonuria, PKU, previously known as SYNB1934. Naming attributes recognize Synlogic’s proprietary technology and the company’s deep appreciation for, and commitment to, the PKU community. “On the heels of initiating Synpheny-3, our pivotal study for people living with PKU, receiving this INN marks another milestone as we advance this potentially transformational therapeutic to the many patients living with PKU who remain in need of a new medical treatment,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “With this name, we recognize PKU heroes: Mary and Sheila Jones, whose experience demonstrated the life-changing effect of Phe control in PKU. Mary and Sheila are honored in the prefix of this INN, ‘marselecobac,’ and it is fitting that we announce this tribute on June 28: International PKU Awareness Day. It is our privilege to share and celebrate this milestone with those living with PKU around the world.”